[1] Lewis GA, Schelbert EB, Williams SG, et al. Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology 2017; 70(17): 2186-200.
[2] Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur J Heart Fail 2018; 20(10): 1385-91.
[3] Rogers MA, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of hospitalization for venous thromboembolism. Circulation 2012; 125(17): 2092-9.
[4] Mamas MA, Sperrin M, Watson MC, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail 2017; 19(9): 1095-104.
[5] Christ M, Stork S, Dorr M, et al. Heart failure epidemiology 2000-2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 2016; 18(8): 1009-18.
[6] Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European heart journal 2014; 35(40): 2797-815.
[7] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-200.
[8] Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40(40): 3297-317.
[9] Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation 2018; 138(9): 861-70.
[10] Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020; 22(8): 1342-56.
[11] Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018; 391(10120): 572-80.
[12] Goyal P, Almarzooq ZI, Horn EM, et al. Characteristics of Hospitalizations for Heart Failure with Preserved Ejection Fraction. Am J Med 2016; 129(6): 635 e15-26.
[13] Streng KW, Nauta JF, Hillege HL, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 2018; 271: 132-9.
[14] Kjeldsen SE, von Lueder TG, Smiseth OA, et al. Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension 2020; 75(1): 23-32.
[15] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726.
[16] Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338-45.
[17] Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456-67.
[18] Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383-92.
[19] Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777-81.
[20] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79(17): e263-e421.
[21] Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451-61.
[22] Empagliflozin ist die erste und einzige zugelassene Behandlung mit belegter Wirksamkeit für die symptomatische, chronische Herzinsuffizienz unabhängig von der Ejektionsfraktion. 07.03.2022 2022. https://www.boehringer-ingelheim.com/de/pressemitteilung/zulassung-symptomatische-chronische-herzinsuffizienz (accessed 16.01.2023 2023).
[23] Fachinformation. Forxiga. Stand Januar 2023.
[24] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381(21): 1995-2008.
[25] Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 2021; 23(7): 1217-25.
[26] Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387(12): 1089-98.
[27] Vaduganathan M, Claggett BL, Jhund P, et al. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA cardiology 2022; 7(12): 1259-63.
[28] Kosiborod M, et al. Präsentiert auf dem AHA 2022; Scientific Sessions; 04.-07. November, 2022, Chicago/virtuell.
[29] Jhund PS, et al. Präsentiert auf dem AHA 2022; Scientific Sessions; 04.-07. November, 2022, Chicago/virtuell.
[30] Adamson C, Kondo T, Jhund PS, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European heart journal 2022; 43(41): 4406-17.
[31] Butt JH, Jhund PS, Belohlavek J, et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation 2022; 146(16): 1210-24.
[32] Butt JH, Kondo T, Jhund PS, et al. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. Journal of the American College of Cardiology 2022; 80(18): 1705-17.
[33] Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology 2022; 80(14): 1302-10.
[34] Inzucchi SE, Claggett BL, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2022; 10(12): 869-81.
[35] Peikert A, Martinez FA, Vaduganathan M, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circ Heart Fail 2022; 15(10): e010080.
[36] Selvaraj S, Vaduganathan M, Claggett BL, et al. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. JACC Heart failure 2023; 11(1): 76-89.
[37] Yang M, Butt JH, Kondo T, et al. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. Eur J Heart Fail 2022; 24(12): 2307-19.
[38] Mc Causland FR, Claggett BL, Vaduganathan M, et al. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA cardiology 2022.
[39] Myhre PL, Vaduganathan M, Claggett BL, et al. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail 2022; 10(12): 902-13.
[40] Ostrominski JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur J Heart Fail 2022; 24(10): 1892-901.
[41] Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022; 28(9): 1956-64.
[42] Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J 2012; 33(17): 2135-42.
